A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).

Simon Pacey,Nimish Shah,Barry R. Davies,Ola Bratt,Anne Y. Warren,Richard D. Baird,Vincent Gnanapragasam,Susan Ingle,Sara Stearn,Andrea Machin,Wendi Qian,Wanfeng Zhao,Elizabeth A. Harrington,Elisabeth Oelmann,Mirela Hategan,Sanjeev Srinivas Kumar,Javier Garcia-Corbacho

A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAP02).

2018

Simon Pacey
Nimish Shah
Barry R. Davies
Ola Bratt
Anne Y. Warren
Richard D. Baird
Vincent Gnanapragasam
Susan Ingle
Sara Stearn
Andrea Machin
Wendi Qian
Wanfeng Zhao
Elizabeth A. Harrington
Elisabeth Oelmann
Mirela Hategan
Sanjeev Srinivas Kumar
Javier Garcia-Corbacho

5081Background: The effect of novel drugs can be studied in primary prostate cancer (PC), if given prior to radical prostatectomy (RP). Altered PI3K/AKT/mTOR signalling is associated with aggressiv...

Keywords:

Prostatectomy
Pathology
Pharmacodynamics
Biomarker (medicine)
Oncology
Medicine
Internal medicine
VISTUSERTIB
mTORC1
Prostate cancer
PI3K/AKT/mTOR pathway
Protein kinase B

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations